$1.72 Billion is the total value of Palo Alto Investors LP's 42 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 15.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ABMD | Sell | ABIOMED INC | $242,294,000 | +7.3% | 1,884,384 | -8.8% | 14.07% | -17.5% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $208,229,000 | +14.4% | 1,763,458 | +2.6% | 12.10% | -12.0% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $165,694,000 | +22.6% | 1,790,899 | +3.1% | 9.62% | -5.7% |
| CLVS | CLOVIS ONCOLOGY INC | $137,137,000 | +162.8% | 3,804,088 | 0.0% | 7.97% | +102.1% | |
| AMAG | Buy | AMAG PHARMACEUTICALS INC | $81,538,000 | +4.1% | 3,326,720 | +1.6% | 4.74% | -19.9% |
| INSM | Buy | INSMED INC | $73,926,000 | +48.3% | 5,091,298 | +0.7% | 4.29% | +14.1% |
| CEMP | Buy | CEMPRA INC | $68,836,000 | +49.8% | 2,844,483 | +2.0% | 4.00% | +15.2% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $68,831,000 | +73.7% | 561,700 | +65.5% | 4.00% | +33.6% |
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $68,402,000 | +44.7% | 4,110,708 | -2.7% | 3.97% | +11.2% |
| WMGI | Buy | WRIGHT MED GROUP N V | $59,865,000 | +43.1% | 2,440,493 | +1.3% | 3.48% | +10.0% |
| PRTA | Buy | PROTHENA CORP PLC | $56,039,000 | +103.3% | 934,455 | +18.5% | 3.26% | +56.3% |
| ZLTQ | Buy | ZELTIQ AESTHETICS INC | $55,479,000 | +45.9% | 1,414,563 | +1.7% | 3.22% | +12.2% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $47,140,000 | +1.0% | 1,481,930 | +3.1% | 2.74% | -22.3% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $42,072,000 | +92.2% | 5,685,388 | +41.8% | 2.44% | +47.8% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $41,539,000 | +229.9% | 902,051 | +115.9% | 2.41% | +153.7% |
| ARIA | Buy | ARIAD PHARMACEUTICALS INC | $35,424,000 | +89.1% | 2,587,617 | +2.1% | 2.06% | +45.4% |
| CELG | Buy | CELGENE CORP | $30,596,000 | +10.9% | 292,700 | +4.7% | 1.78% | -14.7% |
| STAA | Buy | STAAR SURGICAL CO | $30,499,000 | +72.6% | 3,244,610 | +1.2% | 1.77% | +32.7% |
| KPTI | Sell | KARYOPHARM THERAPEUTICS INC | $30,025,000 | +42.5% | 3,085,849 | -1.7% | 1.74% | +9.6% |
| EPZM | Buy | EPIZYME INC | $27,695,000 | -0.3% | 2,814,540 | +3.8% | 1.61% | -23.3% |
| GILD | GILEAD SCIENCES INC | $25,192,000 | -5.2% | 318,400 | 0.0% | 1.46% | -27.1% | |
| SHPG | Buy | SHIRE PLCsponsored adr | $23,884,000 | +8.8% | 123,200 | +3.3% | 1.39% | -16.4% |
| MNTA | Buy | MOMENTA PHARMACEUTICALS INC | $19,299,000 | +9.7% | 1,650,876 | +1.3% | 1.12% | -15.7% |
| ENDP | Buy | ENDO INTL PLC | $19,048,000 | +32.3% | 945,330 | +2.4% | 1.11% | +1.7% |
| RIGL | Sell | RIGEL PHARMACEUTICALS INC | $19,033,000 | +58.4% | 5,186,088 | -3.7% | 1.11% | +21.9% |
| EXAS | Buy | EXACT SCIENCES CORP | $7,372,000 | +51.9% | 396,976 | +0.2% | 0.43% | +16.6% |
| ACRX | Buy | ACELRX PHARMACEUTICALS INC | $6,359,000 | +65.9% | 1,634,608 | +14.7% | 0.37% | +27.2% |
| AIMT | Buy | AIMMUNE THERAPEUTICS INC | $5,696,000 | +61.7% | 379,727 | +16.6% | 0.33% | +24.4% |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $5,080,000 | – | 1,162,473 | +100.0% | 0.30% | – |
| ALIM | ALIMERA SCIENCES INC | $4,491,000 | +21.1% | 3,013,793 | 0.0% | 0.26% | -6.8% | |
| ALGN | Buy | ALIGN TECHNOLOGY INC | $3,512,000 | +19.9% | 37,457 | +3.0% | 0.20% | -7.7% |
| IDRA | IDERA PHARMACEUTICALS INC | $3,220,000 | +67.4% | 1,257,748 | 0.0% | 0.19% | +29.0% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $1,575,000 | +95.9% | 267,890 | 0.0% | 0.09% | +49.2% | |
| HSGX | HISTOGENICS CORP | $1,459,000 | +87.8% | 454,545 | 0.0% | 0.08% | +44.1% | |
| XON | INTREXON CORP | $1,320,000 | +13.9% | 47,100 | 0.0% | 0.08% | -12.5% | |
| CYTK | CYTOKINETICS INC | $1,135,000 | -3.3% | 123,686 | 0.0% | 0.07% | -25.8% | |
| SPHS | Sell | SOPHIRIS BIO INC | $768,000 | -27.7% | 247,000 | -50.0% | 0.04% | -43.8% |
| ADHD | ALCOBRA LTD | $674,000 | -45.0% | 272,788 | 0.0% | 0.04% | -58.1% | |
| OREXQ | New | OREXIGEN THERAPEUTICS INC | $555,000 | – | 167,302 | +100.0% | 0.03% | – |
| ZGNX | ZOGENIX INC | $337,000 | +42.2% | 29,500 | 0.0% | 0.02% | +11.1% | |
| QURE | UNIQURE NV | $156,000 | +3.3% | 20,453 | 0.0% | 0.01% | -18.2% | |
| MRNS | MARINUS PHARMACEUTICALS INC | $116,000 | +43.2% | 63,517 | 0.0% | 0.01% | +16.7% | |
| OREX | Exit | OREXIGEN THERAPEUTICS INC | $0 | – | -1,673,024 | -100.0% | -0.05% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -6,974,854 | -100.0% | -0.29% | – |
| SQNM | Exit | SEQUENOM INC | $0 | – | -10,322,377 | -100.0% | -0.71% | – |
| HTWR | Exit | HEARTWARE INTL INC | $0 | – | -272,986 | -100.0% | -1.19% | – |
| MDVN | Exit | MEDIVATION INC | $0 | – | -273,983 | -100.0% | -1.25% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Biomarin Pharmaceuticals, Inc | 42 | Q3 2023 | 16.6% |
| UNITED THERAPEUTICS CORP DEL | 42 | Q3 2023 | 15.3% |
| INSMED INC | 42 | Q3 2023 | 14.1% |
| STAAR Surgical Company | 42 | Q3 2023 | 11.8% |
| AMICUS THERAPEUTICS INC | 42 | Q3 2023 | 12.1% |
| VANDA PHARMACEUTICALS INC | 42 | Q3 2023 | 5.8% |
| PROTHENA CORP PLC | 42 | Q3 2023 | 9.1% |
| CYTOKINETICS INC | 40 | Q3 2023 | 0.4% |
| ALIGN TECHNOLOGY INC | 39 | Q3 2023 | 2.5% |
| ABIOMED INC | 38 | Q3 2022 | 17.1% |
View Palo Alto Investors LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ALIMERA SCIENCES INCSold out | April 03, 2023 | 0 | 0.0% |
| Epizyme, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| INSMED Inc | February 14, 2023 | 5,871,291 | 4.3% |
| Vanda Pharmaceuticals Inc. | February 14, 2023 | 1,087,064 | 1.4% |
| ALIMERA SCIENCES INC | February 14, 2022 | 802,423 | 11.6% |
| Clovis Oncology, Inc. | February 14, 2022 | 3,997,826 | 3.1% |
| STAAR SURGICAL CO | February 14, 2022 | 1,140,511 | 2.4% |
| Aimmune Therapeutics, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| AMAG PHARMACEUTICALS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
| ALIMERA SCIENCES INC | February 14, 2020 | 802,424 | 16.2% |
View Palo Alto Investors LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-04-03 |
| 4 | 2023-03-28 |
View Palo Alto Investors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.